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The Global Programme to Eliminate Lymphatic Filariasis (LF) is using mass drug administration (MDA) of antifilarial medications to treat filarial infections, prevent disease and interrupt transmission. Almost 500 million people
receive these medications each year. Clinical trials have recently shown that a single dose of a triple-drug combination comprised of ivermectin, diethylcarbamazine and albendazole (IDA) is dramatically superior to widely
used two-drug combinations for clearing larval filarial parasites from the blood of infected persons. A large multicenter community study showed that IDA was well-tolerated when it was provided as MDA. IDA was rapidly
advanced from clinical trial to policy and implementation; it has the potential to accelerate LF elimination in
many endemic countries.
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Introduction

A triple-drug MDA regimen for LF elimination

The Global Programme to Eliminate Lymphatic Filariasis (GPELF),
launched by the World Health Organization (WHO) in 2000, aims
to eliminate lymphatic filariasis (LF) as a public health problem.1
The Programme has two pillars, namely mass drug administration (MDA) with antifilarial drugs (to cure infections and reduce
transmission of new infections) and protocols for morbidity management and disability prevention (MMDP) to help persons with
clinically overt LF (lymphedema, elephantiasis and hydrocele).
Other papers in this collection describe GPELF and the doubledrug regimens (ivermectin plus albendazole and diethylcarbamazine (DEC) plus albendazole) that have been used for MDA
since its inception. While those treatments have strong antifilarial activity, neither results in complete cures (death of all adult
worms) or achieves sustained, complete clearance of microfilaremia (Mf) in a majority of infected persons after a single dose.
Long-lasting Mf clearance is desirable, because blood Mf are required for transmission of new filarial infections by mosquitoes.
This paper will review clinical development of the triple-drug regimen IDA that is comprised of ivermectin plus diethylcarbamazine
and albendazole; the review process for policy change; and IDA’s
rapid uptake by LF elimination programs.

The DOLF Project is a large consortium for research on selected
neglected tropical diseases that was funded by the Bill & Melinda
Gates Foundation in 2010 (www.dolf.wustl.edu). One of the major objectives of DOLF was to conduct clinical trials and community treatment studies to optimize use of approved drugs to try
to improve the impact of MDA to accelerate elimination programs
for LF and onchocerciasis. DOLF plans research projects with input
from key stakeholders. It also provides technical support for field
studies that are conducted by colleagues and staff from health
ministries and/or academic institutions in disease-endemic
countries.
While the idea of triple-drug therapy for LF was not novel, DOLF
conducted the first clinical trials that compared the tolerability
and efficacy of IDA (a single oral dose of ivermectin 200 μg/kg
plus 6 mg/kg of DEC and 400 mg of albendazole) to two-drug
MDA regimens that are recommended by WHO, namely DEC plus
albendazole (DA) and ivermectin plus albendazole (IA).
Preliminary pharmacokinetic studies showed that there were
no clinically significant interactions between the three drugs.2
Clinical trials in heavily infected individuals showed that IDA
was more effective than DA for achieving sustained clearance
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Steps that led to policy change
Transmission modeling studies suggested that MDA with IDA
(with moderate to high compliance) should reduce the number
of rounds of MDA required to eliminate LF (defined in the study as
achieving a true Mf prevalence of <1%) compared to the number of rounds that would be required to reach the elimination
threshold with the two-drug MDA regimens.6 External stakeholders advised the DOLF team that additional evidence would be required before IDA could be recommended for widespread use in
LF elimination programs. Tolerability is a top priority for MDA programs, and the small clinical trials (conducted in heavily infected
subjects) had shown that mild to moderate adverse events were
sometimes more common after IDA treatment than after DA or
IA. Clearly, additional evidence was needed to assess the tolerability of IDA in community settings. WHO advised assessing the
frequency of adverse events in communities receiving IDA MDA
through a strategy of cohort event monitoring.7 Therefore, DOLF
researchers conducted large-scale community studies that compared the prevalence and severity of AEs following MDA with either IDA or DA.8 The studies were performed in carefully selected
sites in five countries with different epidemiological characteristics. Three studies were performed in W. bancrofti-endemic areas (in India, Fiji and Haiti) that had persistent LF despite five or
more prior rounds of MDA with DA. Two studies were performed in
treatment-naïve areas in PNG and Indonesia that were endemic
for W. bancrofti and B. timori, respectively. Results from more than
26 000 participants showed that overall AE rates, types and severity were the same after IDA and DA.8 AE rates were higher after
IDA than after DA in persons with microfilaremia, but severe or serious AEs were no more common after IDA than after DA. These
results indicated that IDA was as well-tolerated as DA for use in
MDA programs. The large dataset from this study (which included
age, height and weight) was used to develop a practical heightbased dosing algorithm to decrease the frequency of persons

receiving less than the recommended dose of DEC that occurs
with age-based dosing.9
A more effective treatment regimen for MDA will not improve
outcomes unless it is acceptable to target populations. Therefore,
acceptability studies were performed in each of the five tolerability study sites several months after MDA. These studies utilized a common protocol that included a survey questionnaire,
focus group sessions and key informant interviews.10 Results of
these studies showed that IDA was as acceptable as DA even
though the IDA regimen contains more tablets. The study identified factors that are likely to affect the acceptability of MDA with
any regimen. These included a well-planned and executed social mobilization program and factors that increased trust in the
program (e.g. clearly identifiable drug distributors who were wellinformed, and a transparent plan for managing AEs that sometimes arise following treatment). Lessons from these acceptability studies and lessons learned from the first countries that have
employed IDA are being used to inform large-scale introduction
of IDA in a number of countries.

Policy changes at WHO and at MSD
One unique aspect of the transition of IDA research findings to
policy was the close coordination and communication between
stakeholders with WHO. The WHO guideline development process was followed and timed appropriately to reduce lag times
between discovery, evidence review and policy development.11
WHO obtained approval to initiate development of a new guideline on MDA in late 2016 based on exciting (but unpublished at
that time) 24-month follow-up data from the IDA PK study and
12-month data from a larger randomized control trial in PNG. After establishing the scope of the new guideline, WHO commissioned systematic reviews to address the specific PICO (patient
population, interventions, comparisons and outcomes) questions
to guide formulation of recommendations. All data from relevant
studies (published and unpublished from DOLF’s registered clinical trials) were shared by researchers and included in the systematic review and meta-analysis. The Guideline Development
Group reviewed the evidence (efficacy, tolerability and acceptability data) and used GRADE procedures (Grading of Recommendations Assessment, Development and Evaluation) to formulate recommendations regarding alternative drug regimens
for MDA.12 The group also considered factors such as resources,
health equity and feasibility; this process led to a conditional
recommendation for the use of IDA in certain settings. Full details of the process and recommendations on other alternative
MDA strategies were published in the new guideline on November 17, 2017.13 Briefly, the policy change endorsed use of IDA
for LF elimination programs in countries without onchocerciasis
that had either not yet started MDA or that were not on track to
reach elimination targets following several rounds of MDA with
DA. Shortly following the release of the guideline, MSD (trade
name of Merck & Co. Inc., Kenilworth, NJ, USA) announced a
substantial increase in their ivermectin donation program of up
to 100 million treatments per year for five years through their
Mectizan Donation Programme to cover projected needs for IDA
in countries without co-endemic onchocerciasis.14 This remarkable outcome was possible because MSD had been informed and
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of Wuchereria bancrofti Mf in Papua New Guinea (PNG); 96% of
IDA recipients were Mf negative three years after a single dose.2,3
Follow-up studies showed that most persons in this trial remained
amicrofilaremic when they were retested almost five years after treatment with a single dose of IDA.4 Similar results (albeit
with shorter follow-up) were obtained in a clinical trial of IDA that
was performed in persons with Brugia timori infections in eastern Indonesia; 96% of persons treated with IDA had complete Mf
clearance by membrane filtration one year after IDA treatment
(T. Supali, personal communication). A clinical trial in Côte d’Ivoire
showed that IDA was much more effective for clearing W. bancrofti Mf and more effective for killing adult filarial worms than
IA, but the Mf clearance effect was not as long-lasting as that
seen in the studies in PNG or Indonesia.5 Seventy-one percent
of IDA recipients were Mf negative by membrane filtration at
12 months compared to 26% after ivermectin plus albendazole.
However, a single treatment with IDA was equivalent to two annual treatments with IA in that setting. Additional work will be
needed to determine whether reappearance of Mf in trial participants in Côte d’Ivoire was due to reinfections after IDA treatment or to a regional difference in parasite susceptibility to IDA
treatment.
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engaged early in the process. Indeed, all study data and modeling results were shared with MSD to inform their internal decisionmaking process.

Even prior to the release of the new guideline, WHO Regional
Offices received requests from endemic countries for a recommendation on IDA and also requests for WHO to recommend
alternative MDA strategies that could accelerate progress toward LF elimination.15 Immediately following the release of the
guideline, WHO organized regional or country-level consultations to review progress, identify where IDA was warranted and
plan according to the decisions by national programs to adopt
IDA. These meetings also provided opportunities for renewed
engagement among stakeholders in support of the national programs’ plans. The first program implementation of IDA occurred
in the Pacific region when Samoa and American Samoa implemented IDA MDA in 2018. The same year, Kenya, Fiji, India and
PNG planned and implemented IDA in pilot districts.16 In 2019,
Guyana, Malaysia, Sao Tome and Principe, Timor Leste and Tuvalu
adopted IDA nationally by providing IDA in all implementation
units (IU) that required MDA. Egypt was the first country to use
IDA in a community setting to address focal persistence of LF
that was detected by post-elimination surveillance. As of May
2020, IDA MDA has already been provided to more than 13 million people in targeted implementation units in 11 countries to
remove the threat of LF transmission and prevent new infections
(WHO unpublished data).

Research questions and future directions
IDA worked better than expected in the clinical trials, and that
was a wonderful surprise. The success of IDA and the roll-outs
have raised additional questions for scientists and for LF elimination programs:
How does IDA work? We do not know why IDA is more effective than IA or DA for clearing Mf. Ultrasound results from clinical
trials suggest that IDA is more effective than IA for killing adult
worms,5 but antigen test results suggest that IDA is no more effective than DA for killing adult worms. Therefore, it is likely that
IDA kills some adult worms and sterilizes others. Additional work
is needed to determine whether this is due to additive effects or
to synergy between IDA components. Since anti-Wolbachia treatments are more effective for sterilizing than killing adult filarial
worms,17 it is possible that IDA’s sterilizing effect on adult worms
is secondary to an indirect effect of the treatment on Wolbachia
endosymbionts.
Are there regional differences in IDA efficacy? While IDA has
worked well in many areas, researchers have noted reduced efficacy of IDA for achieving sustained clearance of Mf in some areas.
More work is needed to determine whether this is due to reinfection or to differences in drug levels or in parasite susceptibility to
the treatment.
Implications of IDA for MDA stopping decisions. Clinical trials
and community MDA studies have shown that IDA is much more
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Lessons from the IDA case study for
accelerated uptake of research advances by
global health programs
Medical research too often focuses on discovery as an end in
itself. The IDA story illustrates what can happen when partners
coordinate their efforts with a focus on the global public health
benefit. Close collaboration and partnership compressed the
time required to move from research advance to policy change
and implementation. A process that normally may have taken
more than 10 years was completed in approximately three years.
We believe that early communication, coordination between key
stakeholders and a focus on steps required for policy change
were the special sauce that led to this success. This collaboration
started early in the DOLF project with close communication
between the researchers and the funding agency. The researchers contacted the funding agency to report the dramatic
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Uptake of the new policy by national
LF-elimination programs

effective for clearing Mf than for clearing CFA. Current WHO protocols for transmission assessment surveys (TAS) and pre-TAS rely
heavily on CFA testing that is performed after at least five rounds
of MDA with two-drug regimens.18 Experts are currently reevaluating these protocols, because CFA prevalences in children or
adults are unlikely to decrease sufficiently to meet current targets
after two rounds of IDA. Since Mf are required for LF transmission,
programs should consider going back to the future in areas where
IDA is used, by basing stopping decisions on a modified version of
Mf monitoring. A two-step process could start with CFA screening of adults to reduce the number of persons who require Mf
testing.
Can IDA be safely deployed in African countries with loiasis or
onchocerciasis? WHO does not recommend use of IDA in these
countries, because DEC can cause serious adverse events in
persons with heavy infections with Loa loa or Onchocerca volvulus. The DOLF project is currently conducting a clinical trial to
determine whether IDA can be safely used in persons with
onchocerciasis after skin and intraocular Mf counts have been
reduced by pretreatment with ivermectin alone.
Will IDA work for other filarial infections (especially onchocerciasis)? This is an interesting and important question that is also
being addressed in the clinical trial mentioned above. O. volvulus
worms are more difficult to kill than W. bancrofti. However, a
well-tolerated treatment that permanently sterilizes adult O.
volvulus would be a game changer for the global programme to
eliminate onchocerciasis.
Off-target impacts of IDA. Ivermectin had not been widely
used in Asia prior to IDA, because MSD’s donation had historically
focused on Africa. Research is needed to document the health
impacts of IDA on ectoparasitic infections, STH and strongyloidiasis, and to assess whether these benefits or marketing of IDA as
a new and improved MDA regimen can improve compliance for
LF elimination programs.
Ivermectin supply. The use of IDA in all areas where warranted
according to current WHO guidelines (especially in Asia) would require ivermectin beyond the committed donation. In such a scenario, additional sources of quality-assured ivermectin will need
to be identified.

International Health

Conclusions
Clinical trials demonstrated that IDA is well-tolerated and more
effective for clearing microfilaremia than prior treatments for LF.
The fact that all components of IDA were previously approved
drugs facilitated the rapid development and acceptance of the
combination treatment. IDA has the potential to accelerate elimination of LF in countries that are not coendemic for onchocerciasis or loiasis. The IDA case study contains important lessons
for those who are keen to accelerate the transition of research
advances into new policies that can be implemented to benefit
patients and populations.
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